We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Forty Seven

News List

Forty Seven, Rocket collaborate on new treatment for Fanconi Anemia pharmaceutical-business-review
March 13, 2020
Forty Seven and Rocket Pharmaceuticals have entered into a research collaboration for evaluating a new treatment regimen in Fanconi Anemia, a rare paediatric disease.
Gilead to Acquire Immuno-Oncology Company Forty Seven for $4.9 Billion biospace
March 04, 2020
Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards.
Gilead to Acquire Forty Seven for $4.9B contractpharma
March 03, 2020
Will gain lead product candidate magrolimab in clinical development for the treatment of several cancers.
Forty Seven’s anti-CD47 combo shows promise in non-Hodgkin lymphoma fiercebiotech
November 02, 2018
An immunotherapy combining Roche’s blood cancer drug Rituxan and an anti-CD47 drug developed at Stanford University shrank the cancers of half the patients in a small phase 1 trial.
Forty Seven raises another $75M to expand I-O trial slate fiercebiotech
October 19, 2017
New backer Wellington Management led the round with the support of Clarus, Lightspeed Venture Partners, Sutter Hill Ventures and GV, the four VCs that drove Forty Seven to its $75 million series A 20 months ago.